719 related articles for article (PubMed ID: 24388010)
1. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.
Bergmann KC; Demoly P; Worm M; Fokkens WJ; Carrillo T; Tabar AI; Nguyen H; Montagut A; Zeldin RK
J Allergy Clin Immunol; 2014 Jun; 133(6):1608-14.e6. PubMed ID: 24388010
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber.
Roux M; Devillier P; Yang WH; Montagut A; Abiteboul K; Viatte A; Zeldin RK
J Allergy Clin Immunol; 2016 Aug; 138(2):451-458.e5. PubMed ID: 27289490
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
4. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P
Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348
[TBL] [Abstract][Full Text] [Related]
5. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
7. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis.
Riechelmann H; Schmutzhard J; van der Werf JF; Distler A; Kleinjans HA
Am J Rhinol Allergy; 2010; 24(5):e104-9. PubMed ID: 21244725
[TBL] [Abstract][Full Text] [Related]
9. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
10. Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children.
Yonekura S; Okamoto Y; Sakurai D; Horiguchi S; Hanazawa T; Nakano A; Kudou F; Nakamaru Y; Honda K; Hoshioka A; Shimojo N; Kohno Y
Allergol Int; 2010 Dec; 59(4):381-8. PubMed ID: 20864799
[TBL] [Abstract][Full Text] [Related]
11. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
14. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy.
Tonnel AB; Scherpereel A; Douay B; Mellin B; Leprince D; Goldstein N; Delecluse P; Andre C
Allergy; 2004 May; 59(5):491-7. PubMed ID: 15080829
[TBL] [Abstract][Full Text] [Related]
15. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial.
Wang DH; Chen L; Cheng L; Li KN; Yuan H; Lu JH; Li H
Laryngoscope; 2013 Jun; 123(6):1334-40. PubMed ID: 23616386
[TBL] [Abstract][Full Text] [Related]
16. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
17. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501
[TBL] [Abstract][Full Text] [Related]
18. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis.
Okamoto Y; Fujieda S; Okano M; Yoshida Y; Kakudo S; Masuyama K
Allergy; 2017 Mar; 72(3):435-443. PubMed ID: 27471838
[TBL] [Abstract][Full Text] [Related]
19. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a once-daily sublingual immunotherapy without escalation regimen in house dust mite-induced allergic rhinitis.
Mun SJ; Shin JM; Han DH; Kim JW; Kim DY; Lee CH; Min YG; Rhee CS
Int Forum Allergy Rhinol; 2013 Mar; 3(3):177-83. PubMed ID: 23044892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]